OnKure Therapeutics (OKUR) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
3 Jun, 2026Opening remarks and agenda
Meeting called to order by the Chair, with introductions of directors, officers, and external representatives present.
Agenda included election of three Class II directors, ratification of the independent auditor, and amendment of the 2024 Equity Incentive Plan.
Board and executive committee updates
Board nominees for Class II directors were R. Michael Carruthers, Valerie M. Jansen, and Edward T. Mathers.
Board recommended votes in favor of all proposals presented.
Shareholder proposals
Proposals included electing three directors, ratifying KPMG as auditor, and amending the equity incentive plan to increase reserved shares by 8% and remove the annual share limit.
Partial view of Summaries dataset, powered by Quartr API
Latest events from OnKure Therapeutics
- Advancing best-in-class PI3Kα pan-mutant inhibitors for major oncology and rare disease markets.OKUR
Corporate presentation - Q2 2026 net loss was $15.3M; $176M cash runway supports IND filings into 2029.OKURQ2 2026
- Pan-mutant selective PI3Kα inhibitors advance toward IND, showing strong efficacy and safety.OKURKOL event
- Q1 2026 net loss was $15.2M; $192.1M cash supports PI3Ka pipeline and operations into 2029.OKURQ1 2026
- 36.1 million shares registered for resale after $150M private placement; financial risks remain.OKURRegistration filing
- Advancing best-in-class PI3Kα pan-mutant inhibitors for major oncology and rare disease markets.OKURCorporate presentation
- Key votes include director elections, auditor ratification, and equity plan amendments.OKURProxy filing
- Shareholders will vote on director elections, auditor ratification, and an expanded equity plan.OKURProxy filing
- Key clinical milestones and a strong cash position highlight progress in PI3Ka-targeted therapies.OKURQ4 2025